

Ministry of Health
Service Delivery Reporting Form

[HIA2]

District name: _____ Facility name: _____ Code: _____ Month: _____ Year: _____

1.0 Child Health and Nutrition					2.0 Maternal Health and Newborn Care				
1.1 Children Under-five Attendance					2.1 Antenatal Care				
Attendance CH (<12 months)	CHN1-005		CHN1-010		CHN1-015		[A] First Antenatal Visits		
Attendance CH (12-59 months)	CHN1-020		CHN1-025		CHN1-030		Visits Before 14 Weeks (1st Trimester)		
Total child health attendance	(Add CHN1-015 + CHN1-030)				CHN1-035		< 20 years old		
Provided with ITN					CHN1-040		IRH1-005		
Attendances from outside this catchment area					CHN1-045		20+ years old		
							Total Visits Before 14 Weeks... (IRH1-005 + IRH1-010)		
							IRH1-015		
							Visits 14-20 Weeks		
							< 20 years old		
							IRH1-020		
							20+ years old		
							IRH1-025		
							Visits 14-20 Weeks... (IRH1-020 + IRH1-025)		
							IRH1-030		
							Above 20 Weeks		
							< 20 years old		
							IRH1-035		
							20+ years old		
							IRH1-040		
							Above 20 Weeks... (IRH1-035 + IRH1-040)		
							IRH1-045		
							Total < 20 years... (Add IRH1-005, -020 & -035)		
							IRH1-050		
							Total 20+ years... (Add IRH1-010, -025 & -040)		
							IRH1-055		
							Total 1st ANC Visits... (Add IRH1-015, -030 & -045)		
							IRH1-060		
							High-risk Pregnancies		
							IRH1-065		
							[B] Follow-up Antenatal Visits		
							2nd ANC visits		
							IRH1-070		
							3rd ANC visits		
							IRH1-075		
							4th ANC visits		
							IRH1-080		
							Total follow up Visits... (Add IRH1-070 thru -080)		
							IRH1-085		
							Total ANC Visits... (Add IRH1-060 & IRH1-085)		
							IRH1-090		
							From outside catchment area		
							IRH1-095		
							[C] Antenatal Screening		
							Initial anaemia screening		
							IRH1-100		
							Diagnosed with Anaemia (below 11 mg/dl)		
							IRH1-105		
							ANC Syphilis screening initial		
							IRH1-110		
							ANC Syphilis screening initial_Reactive		
							IRH1-115		
							ANC Syphilis screening subsequent		
							IRH1-120		
							ANC Syphilis screening subsequent_Reactive		
							IRH1-125		
							ANC Syphilis treated		
							IRH1-127		
							[D] Non-HIV Prophylaxis		
							IPTp 1		
							IRH1-130		
							IPTp 2		
							IRH1-135		
							IPTp 3		
							IRH1-140		
							IPTp 4		
							IRH1-143		
							Provided with ITN		
							IRH1-145		
							Provided with Iron		
							IRH1-150		
							Provided with Folate		
							IRH1-155		
							Tetanus Toxoid (TT2+)		
							IRH1-160		
							Dewormed		
							IRH1-165		
							[E] Tuberculosis Services in ANC		
							Suspected with TB		
							IRH1-170		
							Referred for TB Treatment		
							IRH1-175		
							Initiated on INH		
							IRH1-180		
1.2 Growth Monitoring and Nutrition					2.2 Postnatal Care				
[A] Weight and Height Assessments					[A] 1st Postnatal visit				
Children weighed	CHN2-005		CHN2-010		CHN2-015		Within 48 Hours		
Children Height/Length taken	CHN2-020		CHN2-025		CHN2-030		IRH2-005		
Both Height and weight measured	CHN2-035		CHN2-040		CHN2-045		From 2-6 days		
Weight for Age (Underweight)							IRH2-010		
between -2Z & -3Z scores	CHN2-050		CHN2-055		CHN2-060		From 7-42 days		
below -3Z scores	CHN2-075		CHN2-080		CHN2-085		IRH2-015		
Height for Age (Stunting)							Total 1st PNC Visits... (Add IRH2-005 to IRH2-015)		
between -2Z & -3Z scores	CHN2-090		CHN2-095		CHN2-100		IRH2-020		
below -3Z scores	CHN2-105		CHN2-110		CHN2-115		1st Postnatal visits after 42 days		
Weight for Height (Wasting/Obesity)							IRH2-025		
between -2Z & -3Z scores	CHN2-120		CHN2-125		CHN2-130		Home Deliveries		
below -3Z scores	CHN2-135		CHN2-140		CHN2-145		IRH2-030		
above +2Z scores	CHN2-150		CHN2-155		CHN2-160		[B] Follow up PNC visit		
Discharged from Nutrition Program	CHN2-165		CHN2-170		CHN2-175		2nd Visit		
							IRH2-035		
							3rd Visit		
							IRH2-040		
							4th Visit		
							IRH2-045		
							Unscheduled follow up visits		
							IRH2-050		
							Total follow-up PNC visits... (Add IRH2-035 to IRH2-050)		
							IRH2-055		
							Total PNC visits... (Add IRH2-020 and IRH2-055)		
							IRH2-060		
							Attendances (antenatal and postnatal)		
							IRH2-065		
							[C] PNC Services Provided		
							Family Planning at 6 weeks		
							IRH2-075		
[B] Vitamin A and Deworming					2.3 Family Planning				
Vitamin A	CHN2-180		CHN2-185		CHN2-190		[A] Attendances		
Dewormed			CHN2-195		CHN2-200		New Acceptor (starting FP method)		
							IRH3-005		
							Repeat visit (already on FP method)		
							IRH3-010		
							Restart (already on FP method)		
							IRH3-015		
							Total FP Visits... (Add IRH3-005 thru IRH3-015)		
							IRH3-020		
[C] Infant Feeding					[A] Family Planning Methods Provided				
Child Feeding counselling (IYCF)	CHN2-205		CHN2-210		CHN2-215		Male condom (# of pieces)		
							IRH3-025		
							Female condom (# of pieces)		
							IRH3-030		
							Combined Oral contraceptives (# of cycles)		
							IRH3-035		
							Progesterone only pill (# of cycles)		
							IRH3-040		
							Medroxyprogesterone injection		
							IRH3-045		
							Norethisterone enanthate injection		
							IRH3-050		
							Implant		
							IRH3-055		
							IUCD inserted		
							IRH3-060		
							Sterilisation - female		
							IRH3-065		
							Sterilisation - male		
							IRH3-070		
1.2 Vaccination					[C] Family Planning Services Provided				
BCG	CHN3-005		CHN3-010		CHN3-015		Screened		
OPV 0	CHN3-020		CHN3-025		CHN3-030		Screened for Breast Cancer		
OPV 1	CHN3-035		CHN3-040		CHN3-045		CSD1-005		
OPV 2	CHN3-050		CHN3-055		CHN3-060		Screened for Cervical Cancer		
OPV 3	CHN3-065		CHN3-070		CHN3-075		CSD1-020		
OPV 4	CHN3-080		CHN3-085		CHN3-090		Screened for Prostate Cancer		
Pentavalent 1	CHN3-095		CHN3-100		CHN3-105		CNS15		
Pentavalent 2	CHN3-110		CHN3-115		CHN3-120		Screened for TB		
Pentavalent 3	CHN3-125		CHN3-130		CHN3-135		IRH3-075		
PCV 1	CHN3-140		CHN3-145		CHN3-150		Treated for STIs		
PCV 2	CHN3-155		CHN3-160		CHN3-165		IRH3-080		
PCV 3	CHN3-170		CHN3-175		CHN3-180		IUCDs removed		
RV 1	CHN3-185		CHN3-190		CHN3-195		IRH3-085		
RV 2	CHN3-200		CHN3-205		CHN3-210		Implants removed		
IPV 1	CHN3-215		CHN3-220		CHN3-225		IRH3-090		
Measles Rubella (<12 months)	CHN3-230		CHN3-235		CHN3-240				
Fully Immunised	CHN3-245		CHN3-250		CHN3-255				
Measles Rubella 2nd Dose (18+ mth)	CHN3-256		CHN3-257		CHN3-258				
Fully Immunised 2					CHN3-260				
Days in a month cold-chain fridge was functional									

[C] Family Planning Services Provided [Continued]		
Screened for HTS Needs_Males	IRH3-095	
Screened for HTS Needs_Females	IRH3-100	
Total Screened for HTS Needs... (IRH3-095 + IRH3-100)	IRH3-105	
Screened for HTS Needs_Couples	IRH3-110	
Tested for HIV_Males	IRH3-135	
Tested for HIV_Females	IRH3-140	
Tested for HIV_Total (IRH3-095 + IRH3-100)	IRH3-145	
Tested for HIV_Couples	IRH3-150	
Referred for HTS	IRH3-155	
2.4 Obstetric Care		
[A] Institutional Deliveries		
Normal Deliveries	IRH4-005	
Assisted Deliveries	IRH4-010	
Caesarean Section	IRH4-015	
Total deliveries in a facility (IRH4-005 thru IRH4-015)	IRH4-020	
[B] Delivery Supervision		
Midwife/ Obstetrician	IRH4-025	
Doctor/Nurse/CO/ML	IRH4-030	
All Skilled Personnel (IRH4-025 plus IRH4-030)	IRH4-035	
Other facility Staff	IRH4-040	
[C] Pregnancy/Delivery Complications		
Obstructed labour	IRH4-050	
Prolonged Labour	IRH4-052	
Pregnancy Induced Hypertension	IRH4-053	
Haemorrhage	IRH4-070	
Abortion (Spontaneous and induced)	IRH4-075	
Ruptured uterus	IRH4-085	
Retained placenta	IRH4-090	
Complications other	IRH4-105	
Complications Total (Add IRH4-045 thru IRH4-105)	IRH4-110	
Maternal Deaths in the facility	IRH4-115	
Maternal Deaths audited	IRH4-120	
Neonatal Deaths audited	IRH4-125	
[C] Emergency Obstetric and Neonatal Care Signal functions and Others		
IV antibiotics for sepsis	IRH4-130	
Magnesium Sulphate for pre-/eclampsia	IRH4-135	
IV oxytocic to prevent haemorrhage	IRH4-140	
Manual removal of placenta	IRH4-145	
Vacuum extraction (Ventouse)	IRH4-150	
Post abortion care	IRH4-155	
Neonatal Resuscitation performed	IRH5-160	
[D] Comprehensive EmONC data elements		
Caesarean Section (refer to IRH4-015 above)		
Blood transfusion during delivery	IRH4-165	
Repair of tears	IRH4-170	
Dilatation & curettage (D&C)	IRH4-175	
Referred for emergency care	IRH4-180	
2.5 Outcome of Delivery		
[A] Live Births		
Birth weight <2500g	IRH5-005	
Birth weight >=2500g	IRH5-010	
Live Births Total (IRH5-005 + IRH5-010)	IRH5-015	
Breastfed within 1hr	IRH5-020	
Birth Asphyxia	IRH5-025	
HIV+ exposed infants	IRH5-030	
Neonatal Sepsis	IRH5-035	
[B] Still Births		
Still Births Macerated	IRH5-040	
Still births Fresh	IRH5-045	
Still Births Total (IRH5-040 + IRH5-045)	IRH5-050	
Still births due to Asphyxia	IRH5-060	

3.0 HIV Prevention, Care and Treatment						
3.1 HIV Testing Services (HTS) (All sources)						
[A] Testing						
		Male		Female		Total
Tested_<1	HIV1-005		HIV1-010		HIV1-015	
Tested_1-4	HIV1-020		HIV1-025		HIV1-030	
Tested_5-9	HIV1-035		HIV1-040		HIV1-045	
Tested_10-14	HIV1-050		HIV1-055		HIV1-060	
Tested_15-19	HIV1-065		HIV1-070		HIV1-075	
Tested_20-24	HIV1-080		HIV1-085		HIV1-090	
Tested_25-49	HIV1-095		HIV1-100		HIV1-105	
Tested_50+	HIV1-110		HIV1-115		HIV1-120	
Tested_Sex	HIV1-125		HIV1-130		HIV1-135	
[B] HIV Positive Results						
		Male		Female		Total
Positive_<1	HIV1-140		HIV1-145		HIV1-150	
Positive_1-4	HIV1-155		HIV1-160		HIV1-165	
Positive_5-9	HIV1-170		HIV1-175		HIV1-180	
Positive_10-14	HIV1-185		HIV1-190		HIV1-195	
Positive_15-19	HIV1-200		HIV1-205		HIV1-210	
Positive_20-24	HIV1-215		HIV1-220		HIV1-225	
Positive_25-49	HIV1-230		HIV1-235		HIV1-240	
Positive_50+	HIV1-245		HIV1-250		HIV1-255	
Positive_Sex	HIV1-260		HIV1-265		HIV1-270	
[C] Client Type						
New clients (ever)	HIV1-275		Tested as a couple	HIV1-285		
Repeat	HIV1-280		Discordant couples	HIV1-290		
[D] HIV Testing Services Delivery Point						
Postnatal (maternal)	HIV1-295		Inpatient	HIV1-320		
Under 5 Clinic	HIV1-300		HIV Care & Treatment	HIV1-325		
Tuberculosis Clinic	HIV1-305		VMMC	HIV1-330		
STI Clinic	HIV1-310		HTS (fixed)	HIV1-335		
OPD	HIV1-315		HTS (community)	HIV1-340		
Other testing points				HIV1-345		
[E] HTS/FP Integration						
		Male		Female		Total
Screened - FP Need	HIV1-350		HIV1-355		HIV1-360	
Unmet need for FP	HIV1-365		HIV1-370		HIV1-375	
Started on FP	HIV1-380		HIV1-385		HIV1-390	
Referred for FP					HIV1-400	
3.2 Elimination of Mother-to-Child Transmission of HIV						
[A] Testing for HIV						
Tested - Initial test in ANC				HIV2-005		
Tested - Initial test in L&D				HIV2-010		
Tested - Initial test in PNC (<6 weeks)				HIV2-015		
Total Initial Tests (Add HIV2-005 to HIV2-015)				HIV2-020		
Known HIV+ at first ANC visit				HIV2-025		
Total with known HIV status (HIV2-020 + HIV2-025)				HIV2-030		
[B] HIV Positive Resu						
Positive - Initial test in ANC				HIV2-035		
Positive - Initial test in L&D				HIV2-040		
Positive - Initial test in PNC (<6 weeks)				HIV2-045		
Positive - Repeat test (ANC, L&D, PNC)				HIV2-050		
Total positive women (Add HIV2-035 to HIV2-050)				HIV2-055		

[C] Maternal ART (PMTCT Continued)						
On ART at 1st ANC visit				HIV2-060		
Started on ART in ANC (Option B+)				HIV2-065		
Started on ART in L&D				HIV2-070		
Started on ART in PNC (within 72 hours)				HIV2-075		
Started ART from (after 72hrs but <6 weeks)				HIV2-080		
Total mothers on ART (Add HIV2-060 to HIV2-080)				HIV2-090		
[D] Retention on PMTCT ARVs						
On Option B+ at 12 months				HIV2-095		
Option B+ Net Cohort at 12 months				HIV2-100		
With VL results available at 12 months				HIV2-105		
With VL suppressed at 12 months				HIV2-110		
[E] Male Partner Involvement						
With known status at 1 st visit to MCH				HIV2-115		
Tested in MCH				HIV2-120		
Positive results (MCH only)				HIV2-125		
Discordant Test Results				HIV2-130		
[F] Infant HIV Exposure Status						
Children born from HIV+ mothers				HIV2-133		
Exposed at Penta 1				HIV2-135		
Unexposed at Penta 1				HIV2-140		
Unknown exposure at Penta 1				HIV2-145		
[G] Infant Prophylaxis						
Started on NVP prophylaxis <6 weeks				HIV2-150		
Started on CTX prophylaxis within 6 weeks				HIV2-155		
[H] Infant HIV Testing and Result						
Initial DNA-PCR Test <8 weeks				HIV2-160		
Initial DNA-PCR Test 2-11 mths				HIV2-165		
Initial Rapid Test 12 mths & thereafter				HIV2-170		
Total initial tests (Add HIV2-160 to HIV2-170)				HIV2-175		
[I] Programme Outcome (at 24 months)						
Infected <8 weeks				HIV2-180		
Infected 2 - 11 months				HIV2-185		
Infected 12 months or later				HIV2-190		
Infected 24 months (Add HIV2-180 to HIV2-190)				HIV2-195		
Uninfected 24 months				HIV2-200		
Unknown outcome at 24 months				HIV2-205		
Net HEI Cohort 24 months				HIV2-210		
3.3 Care and Treatment						
[A] Enrolled in Care						
		Male		Female		Total
Enrolled in Care <1	HIV3-005		HIV3-010		HIV3-015	
Enrolled in Care 1-4	HIV3-020		HIV3-025		HIV3-030	
Enrolled in Care 5-9	HIV3-035		HIV3-040		HIV3-045	
Enrolled in Care 10-14	HIV3-050		HIV3-055		HIV3-060	
Enrolled in Care 15-19	HIV3-065		HIV3-070		HIV3-075	
Enrolled in Care 20-24	HIV3-080		HIV3-085		HIV3-090	
Enrolled in Care 25-49	HIV3-095		HIV3-100		HIV3-105	
Enrolled in Care 50+	HIV3-110		HIV3-115		HIV3-120	
Total Enrolled in Care	HIV3-125		HIV3-130		HIV3-135	
Linked to care within 1 month (of testing positive)					HIV3-140	

[B] Currently in Care (Care and Treatment)		Male	Female	Total
In Care_< 1	HIV3-160		HIV3-165	HIV3-170
In Care_ 1-4	HIV3-175		HIV3-180	HIV3-185
In Care_ 5-9	HIV3-190		HIV3-195	HIV3-200
In Care_10-14	HIV3-205		HIV3-210	HIV3-215
In Care_15-19	HIV3-220		HIV3-225	HIV3-230
In Care_20-24	HIV3-235		HIV3-240	HIV3-245
In Care_25-49	HIV3-250		HIV3-255	HIV3-260
In Care_50+	HIV3-265		HIV3-270	HIV3-275
Total In Care_Sex	HIV3-280		HIV3-285	HIV3-290

[C] Started on ART		Male	Female	Total
Started ART_< 1	HIV3-295		HIV3-300	HIV3-305
Started ART_ 1-4	HIV3-310		HIV3-315	HIV3-320
Started ART_ 5-9	HIV3-325		HIV3-330	HIV3-335
Started ART_10-14	HIV3-340		HIV3-345	HIV3-350
Started ART_15-19	HIV3-355		HIV3-360	HIV3-365
Started ART_20-24	HIV3-370		HIV3-375	HIV3-380
Started ART_25-49	HIV3-385		HIV3-390	HIV3-395
Started ART_50+	HIV3-400		HIV3-405	HIV3-410
Total Started ART	HIV3-415		HIV3-420	HIV3-425
StartART_Pregnant (Not started in PMTCT/ANC setting)				HIV3-430
StartART_Breast Feeding				HIV3-435

[D] Currently on ART		Male	Female	Total
Current on ART_< 1	HIV3-455		HIV3-460	HIV3-465
Current on ART_ 1-4	HIV3-470		HIV3-475	HIV3-480
Current on ART_ 5-9	HIV3-485		HIV3-490	HIV3-495
Current on ART_10-14	HIV3-500		HIV3-505	HIV3-510
Current on ART_15-19	HIV3-515		HIV3-520	HIV3-525
Current on ART_20-24	HIV3-530		HIV3-535	HIV3-540
Current on ART_25-49	HIV3-545		HIV3-550	HIV3-555
Current on ART_50+	HIV3-560		HIV3-565	HIV3-570
Total Current on ART	HIV3-575		HIV3-580	HIV3-585

[E] Events in ART		Male	Female	Total
Trans-Ins	HIV3-436		HIV3-460	HIV3-465
Trans-Outs	HIV3-470		HIV3-475	HIV3-495
Lossed to follow up	HIV3-485		HIV3-490	HIV3-495
Deaths	HIV3-500		HIV3-505	HIV3-510

[F] On CTX/Dapsone		Male	Female	Total
On CTX_< 1 yr	HIV3-590			
On CTX_ 1-4 yrs	HIV3-595			
On CTX_ 5-9 yrs	HIV3-600			
On CTX_10-14 yrs	HIV3-605			
On CTX_15-19 yrs	HIV3-610			
On CTX_20-24 yrs	HIV3-615			
On CTX_25-49 yrs	HIV3-620			
On CTX_50+ yrs	HIV3-625			
On CTX / Add 3-590 to -625	HIV3-630			

[I] Screening in HIV Care		Male	Female	Total
Tuberculosis				
Screened for TB_<1 yr	HIV3-635		Started INH_<1 yr	HIV3-655
Screened for TB_1-14 yrs	HIV3-640		Started INH_1-14 yrs	HIV3-660
Screened for TB_15+ yrs	HIV3-645		Started INH_15+ yrs	HIV3-665
TB Screen / Add 3-635 to -64	HIV3-650		Start INH / Add 3-655 to -66	HIV3-670
Unmet Need for FP				
Unmetneed for FP_Male	HIV3-675			
Unmetneed for FP_Female	HIV3-680			
Unmetneed for FP_Total	HIV3-685			
Cervical cancer	HIV3-690			

(Care and Treatment Continued)		Male	Female	Total
[J] Timing of Drug Pickups				
On time pick up	HIV3-695		HIV3-700	HIV3-705
1-2 months late	HIV3-710		HIV3-715	HIV3-720
3 months late or more	HIV3-725		HIV3-730	HIV3-735

[K] Retention and Outcomes at 12 months on ART		Male	Female	Total
Net Cohort at 12 months				
All patients	HIV3-740		Pregnant/Breastfeeding	HIV3-745
Still Alive and on ART this month (12 mths later)				
Original 1st Line	HIV3-750		2nd Line or higher	HIV3-760
Alternative 1st line	HIV3-755		Pregnant/Breastfeeding	HIV3-765

[L] Viral load suppression		Male	Female	Total
With records were reviewed for VL				
Tested_<1	HIV3-080		HIV3-085	HIV3-090
Tested_1-14	HIV3-080		HIV3-085	HIV3-090
Tested_15+ yrs	HIV3-095		HIV3-100	HIV3-105
Clients with undetectable viral load				
Suppressed_< 1	HIV3-110		HIV3-115	HIV3-120
Suppressed_1-14	HIV3-110		HIV3-115	HIV3-120
Suppressed_15+ yrs	HIV3-125		HIV3-130	HIV3-135

[M] CD4 Count Assessment		Male	Female	Total
CD4 below 25%_<10	HIV3-140		HIV3-145	HIV3-150
CD4 below 350_<10+	HIV3-155		HIV3-160	HIV3-165

3.4 Voluntary Medical Male Circumcision

[A] Number circumcised		Male	Female	Total
Circumcised_0-2 months			HIV4-005	
Circumcised_3-11 months			HIV4-010	
Circumcised_1-9 years			HIV4-015	
Circumcised_10-14 years			HIV4-020	
Circumcised_15-19 years			HIV4-025	
Circumcised_20-24 years			HIV4-030	
Circumcised_20-29 years			HIV4-035	
Circumcised_30-49 years			HIV4-040	
Circumcised_50+ years			HIV4-045	
Total Circumcised (Add HIV4-005 to -045)			HIV4-050	

[B] HIV Testing Services under VMI		Male	Female	Total
Tested_HIV+			HIV4-055	
Tested_HIV-			HIV4-060	
Known Positive			HIV4-065	
Not tested for HIV			HIV4-070	
Referred for ART			HIV4-075	

[C] MC Procedures		Male	Female	Total
Dorsal Slit			HIV4-080	
Devices			HIV4-085	
Other			HIV4-090	

[D] Circumcision Events		Male	Female	Total
AE_During_Moderate	HIV4-095		AE_Post_Moderate	HIV4-110
AE_During_Severe	HIV4-100		AE_Post_Moderate	HIV4-120
Total AE_During	HIV4-105		Total AE_Post	HIV4-130
Clients coming for Review				HIV4-135

3.5 Post Exposure Prophylaxis		Male	Female	Total
[A] Type of Exposure				
Occupational	HIV5-005		HIV5-010	HIV5-015
Sexual Assault < 5 years	HIV5-020		HIV5-025	HIV5-030
Sexual Assault 5-16 years	HIV5-035		HIV5-040	HIV5-045
Sexual Assault 16+ years	HIV5-050		HIV5-055	HIV5-060
Other exposures	HIV5-065		HIV5-070	HIV5-075
Total Expose... (Add ABOVE)	HIV5-080		HIV5-085	HIV5-090

[B] PEP Provided		Male	Female	Total
Occupational	HIV5-095		HIV5-100	HIV5-105
Sexual Assault < 5 years	HIV5-110		HIV5-115	HIV5-120
Sexual Assault 5-16 years	HIV5-125		HIV5-130	HIV5-135
Sexual Assault 16+ years	HIV5-140		HIV5-145	HIV5-150
Other exposures	HIV5-155		HIV5-160	HIV5-165
Provided with PEP... (Add ABOVE)	HIV5-170		HIV5-175	HIV5-180
Provided with P:EP	HIV5-173		HIV5-177	HIV5-183

4.0 General and Curative Care

4.1 Malaria Services and Cases

[A] Testing		Male	Female	Total
RDT				
Tested_<1 years	Mal1-005		Mal1-010	Mal1-015
Tested_1-5 years	Mal1-020		Mal1-025	Mal1-030
Tested_>5 years	Mal1-035		Mal1-040	Mal1-045
Total... (add ABOVE)	Mal1-065		Mal1-070	Mal1-075
Tested_Pregnant Women	Mal1-080		Mal1-085	Mal1-090
Microscopy				
Tested_<1 years	Mal1-100		Mal1-105	Mal1-110
Tested_1-5 years	Mal1-125		Mal1-130	Mal1-135
Tested_>5 years	Mal1-140		Mal1-145	Mal1-150
Total positive/confirmed (add ABOVE)	Mal1-160		Mal1-165	Mal1-170
Tested Positive/confirmed_Pregnant Women	Mal1-175		Mal1-180	Mal1-185

[B] Malaria Positive/confirmed Results		Male	Female	Total
RDT				
Positive/confirmed_<1 years	Mal1-100		Mal1-105	Mal1-110
Positive/confirmed_1-5 years	Mal1-125		Mal1-130	Mal1-135
Positive/confirmed_>5 years	Mal1-140		Mal1-145	Mal1-150
Total positive/confirmed (add ABOVE)	Mal1-160		Mal1-165	Mal1-170
Tested Positive/confirmed_Pregnant Women	Mal1-175		Mal1-180	Mal1-185
Microscopy				
Confirmed cases treated with antimalarials_<1	Mal1-100		Mal1-105	Mal1-110
Confirmed cases treated with antimalarials_1-5	Mal1-125		Mal1-130	Mal1-135
Confirmed cases treated with antimalarials_>5	Mal1-140		Mal1-145	Mal1-150
Total... (add ABOVE)	Mal1-160		Mal1-165	Mal1-170
Confirmed cases treated with antimalarial_Pregnant Women	Mal1-175		Mal1-180	Mal1-185
Clinical cases treated with antimalarials_<1 years	Mal1-100		Mal1-105	Mal1-110
Clinical cases treated with antimalarials_1-5 years	Mal1-125		Mal1-130	Mal1-135
Clinical cases treated with antimalarials_>5 years	Mal1-140		Mal1-145	Mal1-150
Total... (add ABOVE)	Mal1-160		Mal1-165	Mal1-170
Clinical cases treated with antimalarial_Pregnant Women	Mal1-175		Mal1-180	Mal1-185

4.2 Ophthalmic Services

[A] Patients treated for eye disease		Male	Female	Total
Less 10 years	OPH1-005		OPH1-010	OPH1-015
10-14 years	OPH1-020		OPH1-025	OPH1-030
15-39 years	OPH1-035		OPH1-040	OPH1-045
40 Years and above	OPH1-050		OPH1-055	OPH1-060
Total Patients treated	OPH1-065		OPH1-070	OPH1-075

[B] Number of patients referred		Male	Female	Total
Less 10 years	OPD1-080		OPD1-085	OPD1-090
10-14 years	OPD1-095		OPD1-100	OPD1-105
15-39 years	OPH1-110		OPD1-115	OPD1-120
40 Years and above	OPH1-125		OPD1-130	OPD1-135
Total Patients Referred	OPD1-140		OPD1-145	OPD1-150

4.3 Sexually Transmitted Infection (STI) Services

[A] STI Notifications

	Male	Female	Total
Slips Issued_ 0-14 years	STI1-005	STI1-010	STI1-015
Slips Issued_ 15+ years	STI1-020	STI1-025	STI1-030
Total....(add ABOVE)	STI1-040	STI1-045	STI1-050

[B] STI Treatment

	Males	Females	Total
STI treated_ 0-14 years	STI1-055	STI1-060	STI1-065
STI treated_ 15+ years	STI1-070	STI1-075	STI1-080
Total....(add ABOVE)	STI1-085	STI1-090	STI1-100
Partner treated fro STI	STI1-105	STI1-110	STI1-120

4.4 Out patients (OPD)

[A] First Attendances

	Male	Female	Total
1-4 years	OPD1-005	OPD1-010	OPD1-015
5-14 years	OPD1-020	OPD1-025	OPD1-030
15+ years	OPD1-035	OPD1-040	OPD1-045
Total....(add ABOVE)	OPD1-050	OPD1-055	OPD1-060
1st Attendances OPD....(add ABOVE)	OPD1-065	OPD1-070	OPD1-075
OPD Consultations due to GBV	OPD1-080	OPD1-085	OPD1-090

[B] Revisits

	Male	Female	Total
1-4 years	OPD1-095	OPD1-100	OPD1-105
5-14 years	OPD1-110	OPD1-115	OPD1-120
15+ years	OPD1-125	OPD1-130	OPD1-135
Total....(add ABOVE)	OPD1-140	OPD1-145	OPD1-150
Revisits OPD - Total....(add ABOVE)	OPD1-155	OPD1-160	OPD1-165

[C] Total OPD Attendances

	Male	Female	Total
Total OPD Attendances(1st + revisits)	OPD1-170	OPD1-175	OPD1-180

4.5 Inpatient Care (IPD)

[A] In Patient Admissions

	Male	Female	Total
<1 year	IPD1-005	IPD1-010	IPD1-015
1-4 years	IPD1-020	IPD1-025	IPD1-030
5-14 years	IPD1-035	IPD1-040	IPD1-045
15+ years	IPD1-050	IPD1-055	IPD1-060
Total....(add ABOVE)	IPD1-065	IPD1-070	IPD1-075

[B] In Patient Discharges

	Male	Female	Total
<1 year	IPD1-080	IPD1-085	IPD1-090
1-4 years	IPD1-095	IPD1-100	IPD1-105
5-14 years	IPD1-110	IPD1-115	IPD1-120
15+ years	IPD1-125	IPD1-130	IPD1-135
Total....(add ABOVE)	IPD1-140	IPD1-145	IPD1-150

[C] Referrals - Out/LAMAs

	Male	Female	Total
Self-discharge	IPD1-155	IPD1-160	IPD1-165
Referred Out			IPD1-170

[D] Inpatient Deaths

	Male	Female	Total
<1 year	IPD1-180	IPD1-185	IPD1-190
1-4 years	IPD1-195	IPD1-200	IPD1-205
5-14 years	IPD1-210	IPD1-215	IPD1-220
15+ years	IPD1-225	IPD1-230	IPD1-235
Total....(add ABOVE)	IPD1-240	IPD1-245	IPD1-250
Within 48 hours	IPD1-255	IPD1-260	IPD1-265

4.6 Neonatal Deaths

Early (0 -7 days)	IPD1-270	
Late (8-28 days)	IPD1-275	
Total Neonatal deaths	IPD1-280	

4.7 Inpatient Utilisation

In patient bed days	IPD1-285	
OPD Qualified staff	IPD1-290	
IPD Qualified staff	IPD1-295	
Number of beds	IPD1-300	

4.8 Cancer Screening and Diagnosis

	CSD1-	Screened	CSD1-	Referred
Breast cancer	CSD1-		CSD1-	
Cervical	CSD1-		CSD1-	
Prostate cancer	CSD1-		CSD1-	

[5] Human Resources

Staff Category	A		B		C		D	
	Number at start of the month		New recruits/trans-in	[-]	Staff losses /Leave	[=]	Number Worked at end of the month	
Doctor		HR1-01		HR2-01		HR3-01		
Medical Licentiate		HR1-02		HR2-02		HR3-02		
Clinical Officer		HR1-03		HR2-03		HR3-03		
Registered Midwife		HR1-04		HR2-04		HR3-04		
Enrolled Midwife		HR1-05		HR2-05		HR3-05		
Certified Midwife		HR1-06		HR2-06		HR3-06		
Registered Nurse		HR1-07		HR2-07		HR3-07		
Enrolled Nurse		HR1-08		HR2-08		HR3-08		
Pharmacy Staff		HR1-09		HR2-09		HR3-09		
Nutrition Staff		HR1-10		HR2-10		HR3-10		
Environment Health		HR1-11		HR2-11		HR3-11		
Other Paramedicals		HR1-12		HR2-12		HR3-12		
Administrative staff		HR1-13		HR2-13		HR3-13		
Support staff		HR1-14		HR2-14		HR3-14		

6.0 Medicines and Supplies Management (MSM) - (Stockouts: Yes=1, No=0)

Doxycycline 100 mg tablet	DRG1-005	
Phenytoin Tablets	DRG1-010	
Any 1st line anti-malarial	DRG1-015	
Amoxicillin 125 mg/5 ml suspension	DRG1-020	
Combined Oral contraceptive	DRG1-025	
Any 1st line ARV drug	DRG1-030	
4 FDC (TB) drug	DRG1-040	
Benzyl penicillin	DRG1-045	
Therapeutic foods	DRG1-047	
Cotrimoxazole 480 mg	DRG1-050	

Medicines and Supplies Management (MSM) - (Stockouts: Yes=1, No=0).....Continued

Cotrimoxazole 480 mg	DRG1-050	
Oxytocin	DRG1-055	
DPT-HepB+Hib vaccine	DRG1-060	
ORS	DRG1-065	
Paracetamol 500 mg	DRG1-070	
Rapid HIV test	DRG1-075	
RPR test	DRG1-080	
RDT test	DRG1-085	
Any 1st line STIs drug	DRG1-090	
Any Anti malaria for IPT	DRG1-095	

7 Environmental Health Services (ENV)

7.1 Inspections

Targeted premises	ENV1-005	Inspected	ENV1-010	in compliance	ENV1-015
Target food inspections	ENV1-020	Food inspections performed	ENV1-025	Resulting in seizure & disposal	ENV1-030
Target water sources to be inspected	ENV1-035	Water sources inspected	ENV1-040		
Total sanitary facilities	ENV1-045	Sanitary facilities inspected	ENV1-050		

Statutory nuisance notices issued	ENV1-055	Statutory nuisance notices	ENV1-060
Prosecutions conducted	ENV1-065	Number convicted/ Fined	ENV1-070

7.2 Sampling

Target food samples to be taken	ENV2-005	Target water samples	ENV2-020
Food samples collected	ENV2-010	Water samples taken	ENV2-025
Food samples in compliance with standard	ENV2-015	Water samples in compliance	ENV2-030
Salt samples to be test for iodine levels	ENV2-035	Salt samples tested with adequate iodine	ENV2-040

7.3 Rodents and Vector Control

Vector/Rodent complaints received	ENV3-005	Vector/Rodent complaints attended to	ENV3-010
Total number of households			ENV3-015
Households having ITNs			ENV3-020
Number of ITNs distributed- Community dist	ENV3-025		
Number of ITNs distributed- Mass campaign	ENV3-027		
Structures targeted for spraying against mosquitoes	ENV3-028	Structures sprayed against mosquitoes	ENV3-030
Estimated tones of refuse generated	ENV3-035	Tones of refuse collected	ENV3-040

8.0 Mortuary Services

Number of BID	MOT1-005	
Number of bodies claimed from mortuary	MOT1-010	
Number of postmortem performed	MOT1-015	
Number of mortuary body-days	MOT1-020	

9.0 HMIS Quality Assurance

Ran out of forms (1=Yes, 0=No)	QAS1-005	Comments.....
--------------------------------	----------	---------------

Prepared by:.....	Designation:	Verified by:.....	Designation:	Received by:.....	Designation:
Signed:.....	Date:.....	Signed:.....	Date:.....	Signed:.....	Date:.....

